» Articles » PMID: 38258816

Providers' Experiences and Perspectives in Treating Patients With Co-Occurring Opioid and Stimulant Use Disorders in the Hospital

Overview
Specialty Psychiatry
Date 2024 Jan 23
PMID 38258816
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The overdose crisis is increasingly characterized by opioid and stimulant co-use. Despite effective pharmacologic treatment for both opioid use disorder (OUD) and contingency management for stimulant use disorders, most individuals with these co-occurring conditions are not engaged in treatment. Hospitalization is an important opportunity to engage patients and initiate treatment, however existing hospital addiction care is not tailored for patients with co-use and may not meet the needs of this population.

Methods: Semi-structured interviews were conducted with hospital providers about their experiences and perspectives treating patients with opioid and stimulant co-use. We used directed content analysis to identify common experiences and opportunities to improve hospital-based treatment for patients with co-use.

Results: From qualitative interviews with 20 providers, we identified 4 themes describing how co-use complicated hospital-based substance use treatment: (1) patients' unstable circumstances impacting the treatment plan, (2) co-occurring withdrawals are difficult to identify and treat, (3) providers holding more stigmatizing views of patients with co-use, and (4) stimulant use is often "ignored" in the treatment plans. Participants also described a range of potential opportunities to improve hospital-based treatment of co-use that fall into 3 categories: (1) provider practice changes, (2) healthcare system changes, and (3) development and validation of clinical tools and treatment approaches.

Conclusions: We identified unique challenges providing hospital addiction medicine care to patients who use both opioids and stimulants. These findings inform the development, implementation, and testing of hospital-based interventions for patients with co-use.

Citing Articles

Cross sectional analysis of an addiction consultation service, substance co-use patterns, and receipt of medications for opioid use disorder during hospitalization.

Shearer R, Bart G, Beebe T, Virnig B, Shippee N, Winkelman T J Subst Use Addict Treat. 2024; 167:209505.

PMID: 39241929 PMC: 11527587. DOI: 10.1016/j.josat.2024.209505.


Contraceptive uptake in postpartum people with and without opioid use disorder and opioid use with co-occurring substance use.

Bello J, Xu K, Salas J, Kelly J, Grucza R Drug Alcohol Depend Rep. 2024; 12:100248.

PMID: 39040479 PMC: 11261297. DOI: 10.1016/j.dadr.2024.100248.


No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder.

Tilhou A, Baldwin M, Alves J Am J Prev Med. 2024; 67(3):464-469.

PMID: 38762205 PMC: 11338722. DOI: 10.1016/j.amepre.2024.05.005.

References
1.
Trivedi M, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T . Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021; 384(2):140-153. PMC: 8111570. DOI: 10.1056/NEJMoa2020214. View

2.
Bunting A, Shearer R, Linden-Carmichael A, Williams A, Comer S, Cerda M . Are you thinking what I'm thinking? Defining what we mean by "polysubstance use.". Am J Drug Alcohol Abuse. 2023; 50(1):1-7. PMC: 10939915. DOI: 10.1080/00952990.2023.2248360. View

3.
Priest K, Englander H, McCarty D . "Now hospital leaders are paying attention": A qualitative study of internal and external factors influencing addiction consult services. J Subst Abuse Treat. 2020; 110:59-65. PMC: 7181883. DOI: 10.1016/j.jsat.2019.12.003. View

4.
Acheson L, Williams B, Farrell M, McKetin R, Ezard N, Siefried K . Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials. Drug Alcohol Rev. 2022; 42(1):7-19. PMC: 10083934. DOI: 10.1111/dar.13511. View

5.
Bhatraju E, Ludwig-Barron N, Takagi-Stewart J, Sandhu H, Klein J, Tsui J . Successful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma. Drug Alcohol Depend. 2020; 215:108253. PMC: 7531192. DOI: 10.1016/j.drugalcdep.2020.108253. View